Edition:
United Kingdom

Dova Pharmaceuticals Inc (DOVA.OQ)

DOVA.OQ on NASDAQ Stock Exchange Global Market

23.73USD
9:00pm BST
Change (% chg)

$-0.13 (-0.54%)
Prev Close
$23.86
Open
$23.85
Day's High
$23.85
Day's Low
$23.20
Volume
40,043
Avg. Vol
92,296
52-wk High
$35.52
52-wk Low
$16.98

Latest Key Developments (Source: Significant Developments)

Dova Pharmaceuticals Reports Qtrly Loss Per Share $0.52
Wednesday, 9 May 2018 

May 9 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 OPERATING AND FINANCIAL RESULTS.QTRLY LOSS PER SHARE $0.52.Q1 EARNINGS PER SHARE VIEW $-0.47 -- THOMSON REUTERS I/B/E/S.  Full Article

Dova Pharmaceuticals Says On April 17, Co, Unit And SVB Entered Loan And Security Agreement
Friday, 20 Apr 2018 

April 20 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS-ON APRIL 17, CO, UNIT AND SVB ENTERED LOAN AND SECURITY AGREEMENT,PURSUANT TO WHICH SVB AGREED TO LEND CO, UNIT OF $20.0 MILLION.DOVA PHARMA SAYS LOAN MATURES ON APRIL 17, 2021 UNLESS CO ACHIEVES SPECIFIED REVENUE MILESTONE, THEN MATURITY DATE TO BE EXTENDED BY A YEAR - SEC FILING.  Full Article

Dova Pharmaceuticals Inc - Supplemental NDA For Avatrombopag in ITP To Be Submitted In Second Half Of 2018
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS PROVIDES UPDATE ON DEVELOPMENT STRATEGY FOR AVATROMBOPAG IN IMMUNE THROMBOCYTOPENIC PURPURA (ITP) AND CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT).DOVA PHARMACEUTICALS INC - SUPPLEMENTAL NDA FOR ITP TO BE SUBMITTED IN SECOND HALF OF 2018.DOVA PHARMACEUTICALS INC - PHASE 3 CLINICAL TRIAL FOR CIT TO BEGIN IN Q2 OF 2018.  Full Article

Dova Pharmaceuticals Announces FDA Acceptance Of The Avatrombopag New Drug Application With Priority Review
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF THE AVATROMBOPAG NEW DRUG APPLICATION (NDA) WITH PRIORITY REVIEW.DOVA PHARMACEUTICALS INC - PDUFA GOAL DATE FOR AN FDA DECISION IS MAY 21, 2018 FOR NDA​.  Full Article

Dova Pharmaceuticals reports third quarter results
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Dova Pharmaceuticals Inc :Dova Pharmaceuticals reports third quarter 2017 operating and financial results.Dova Pharmaceuticals Inc - qtrly ‍net loss per share, basic and diluted $0.38​.  Full Article

BRIEF-Dova Pharmaceuticals Announces U.S. FDA Approval Of Doptelet

* DOVA PHARMACEUTICALS ANNOUNCES U.S. FDA APPROVAL OF DOPTELET® (AVATROMBOPAG)